Skip to content
Advertisement

John Burkhardt, left, senior vice president of drug safety R&D and head of the Pfizer Groton site speaks at a press conference at Pfizer Groton on the companies research to develop a vaccine for COVID-19, as Connecticut Gov. Ned Lamont stands by to answer questions Wednesday, July 22, 2020, in Groton, Conn. The federal government has agreed to pay nearly $2 billion for 100 million doses of a potential COVID-19 vaccine being developed by the U.S. drugmaker and its German partner BioNTech. (AP Photo/Stew Milne)

John Burkhardt, left, senior vice president of drug safety R&D and head of the Pfizer Groton site speaks at a press conference at Pfizer Groton on the companies research to develop a vaccine for COVID-19, as Connecticut Gov. Ned Lamont stands by to answer questions Wednesday, July 22, 2020, in Groton, Conn. The federal government has agreed to pay nearly $2 billion for 100 million doses of a potential COVID-19 vaccine being developed by the U.S. drugmaker and its German partner BioNTech. (AP Photo/Stew Milne)

Featured Photo Galleries